natgillin/translations-raw huggingface dataset:
Rekonstituér indholdet af hætteglasset med 1,2 ml sterilt vand til injektionsvæsker og brug helst en 2-3 ml sprøjte og en 21G nål.
Reconstitute the contents of the vial with 1.2 mL of sterile water for injection preferably using a 2 to 3 ml syringe and a 21G needle.
Rekonstituér indholdet i hvert Ilaris hætteglas ved stuetemperatur (typisk 15°C til 25°C) ved langsomt at injicere 1,0 ml vand til injektionsvæsker som er trukket op fra hætteglasset med solvens.
Reconstitute the content of Ilaris vial at room temperature (typically 15°C to 25°C) by slowly injecting 1.0 ml of water for injections withdrawn from the solvent vial.
Rekonsttueringen resulterer i en klar, farveløs opløsning.
The reconstituted preparation results in a clear, colourless solution.
Rekrutteringsstatus vil blive
Progress on enrolment will be submitted
rektal blødning
rectal bleeding
Rektal blødning
Rectal haemorrhage
Rektal blødning
Rectal hemorrhage
Rektal blødning
Sucrose
rektal blødning, gastritis. opkastning, dyspepsi, opsvulmet mave, konstipation,
rectal haemorrhage, gastritis, vomiting, dyspepsia, abdominal bloating, constipation,
Rektal blødning, gingival blødning
Abnormal vaginal haemorrhage, urogenital haemorrhage
Rektaltemperaturen bør derefter blive normale værdier igen.
Ten rectal temperatures should then return to normal values.
Rektaltemperaturen bør derefter blive normale værdier.
Rectal temperatures should then return to normal values.
Rektangulære, hvide/beige tabletter med afrundede hjørner og mærket med et omrids af en knogle på den ene side og ”270” på den anden.
Modified rectangle-shaped, white to off-white tablets, marked with an outline of a bone image on one side, and '270' on the other.
Relaps patienter (voksne):
Relapse patients (adults):
relaterede
infusion-related
relaterede
Not known
relaterede
related reactions4, angioedema
relaterede bivirkninger, inklusive
associated adverse events, including
relaterede til
Sofosbuvir:
relateret AIS
related AIS
relateret akut,
acute reversible thrombocytopenia
relateret akut,
depression, nervousness,
relateret akut,
related reactions4, angioedema
relateret CIN 3
related CIN 3
Relateret til centralt venekateter (CVAD)
Related to central venous access devices (CVAD)
Relateret til ChondroCelect
Related to ChondroCelect:
Relateret til MACI:
Related to MACI:
Relation mellem koncentration og effekt
Relationship between concentration and effect
Relation mellem koncentration og effekt:
Relationship between concentration and effect
Relativ biotilgængelighed af fentanyl fra behandling med PecFent sammenlignet med 200 mikrogram OTFC var ca.
Relative bioavailability of fentanyl from the PecFent treatment compared to the 200 microgram OTFC was approximately
Relativ forbedring af C-reaktiv protein (CRP)-niveauet blev observeret i forhold til placebogrupperne, og behandling med Simponi resulterede i signifikant reduktion i forhold til baseline af serum niveauer for IL-6, ICAM-1, matrix-metalloproteinase (MMP)-3 og vascular endothelial growth factor (VEGF) sammenlignet med kontrolbehandling.
Improvement in C-reactive protein (CRP) levels were observed relative to placebo groups and treatment with Simponi resulted in significant reductions from baseline in serum levels of IL-6, ICAM-1, matrix-metalloproteinase (MMP)-3 and vascular endothelial growth factor (VEGF) compared to control treatment.
Relativ forventet %
Relative % predicted
Relativ middeldifference (%)
Relative mean change (%)
Relativ Potency (ELISA test) ved sammenligning med referencevaccine
Relative potency (ELISA test) by comparison with a reference vaccine
Relativ Potency (ELISA test) ved sammenligning med referencevaccine.
Relative potency (ELISA test) by comparison with a reference vaccine.
Relativ reduktion i forekomst1)
Relative rate reduction(1)
Relativ risiko
Relative Risk
Relativ risiko (95 % CI) for GvHD og BRM efter behandling med G-CSF efter knoglemarvstransplantation
Relative risk (95% CI) of GvHD and TRM following treatment with G-CSF after bone marrow transplantation
Relativ risiko (95 % KI) 3-måneders vedvarende progression uge 108
Hazard ratio (CI95%) 3-month Sustained Disability Progression week 108
Relativ risiko (95 % KI) 6-måneders vedvarende progression uge 108
Hazard ratio (CI95%) 6-month Sustained Disability Progression week 108
Relativ risiko (95% CI) for GvHD og TRM
Relative Risk (95% CI) of GvHD and TRM
Relativ risiko for sammenligning af dapagliflozin med komparator var
The hazard ratio comparing dapagliflozin to comparator was
Relativ Risiko Reduktion af kliniske vertebrale frakturer
Relative risk reduction of clinical vertebral fracture
Relativ risiko- reduktion
Relative risk reduction
Relativ risiko- reduktion (97,5 % CI)
Relative Risk Reduction (97.5% CI)
Relativ risiko- reduktion (99 % CI)
Relative risk reduction (99% CI)
Relativ risikoreduk tion (95% CI) vs. placebo
Relative risk reduction (95% CI) vs. placebo
Relativ risikoreduktion i frakturincidens
Relative risk reduction in fracture incidence
Relativ risikoreduktion versus  placebo (95 % CI), p-værdi
Relative Risk Reduction vs. placebo (95%CI), p value
Relativ ændring fra baseline til dag 28 LS-middelværdi (SE)
Relative change from Baseline to Day 28 LS Mean (SE)
Relativ ændring i
Relative change in ppFEV1 at Week 24 (%)
Relativt få patienter inkluderet i fase III-studiet var < 5 år postmenopausalt og mellem 45 og 54 år (2 – 3 %).
Relatively few patients less than 5 years postmenopausal and 45-54 years of age were enrolled in the phase III study (2-3%).
Relevansen af denne observation for klinisk brug til patienter kan ikke udelukkes.
The relevance of this finding for the therapeutic use in patients can not be excluded.
Relevansen af dette fund er – som for andre trombopoietin-receptor(TPO-R)-agonister endnu ikke fastslået.
The relevance of this finding, as with other thrombopoietin receptor (TPO-R) agonists, has not been established yet.
Relevansen af disse fund for mennesker er aktuelt ukendt.
The human relevance of these findings is currently unknown.
Relevansen af disse fund for ritonavir-boostet indinavir kendes ikke.
The relevance of these findings for ritonavir boosted indinavir is unknown.
Relevansen af disse resultater for mennesker over 6 år er ukendt.
The relevance of these results to humans greater than 6 years of age is unknown.
Relevansen for klinisk beskyttelse kendes imidlertid ikke.
However the relevance for clinical protection is unknown.
Relevansen in vivo er ikke kendt.
The in vivo relevance is unknown.
relevant
higher doses of
relevant
medically relevant
relevant
Not Applicable
relevant
peripheral
Relevant information om NEURACEQ som PET sporingsstof for β-amyloid, inklusive den godkendte indikation ifølge produktresuméet, begrænsninger for anvendelse af NEURACEQ, fortolkningsfejl, sikkerhedsinformation og resultaterne af kliniske forsøg, der informerer om den diagnostiske anvendelse af NEURACEQ
Relevant information on NEURACEQ as anβ-amyloid PET tracer, including the approved indication according to the SmPC, limitations of NEURACEQ use, interpretation errors, safety information and the results of clinical trials informing on the diagnostic use of NEURACEQ;
Relevant information om risikoen for blødning
Relevant information on the risk of bleeding
Relevant medicinsk behandling og overvågning skal være umiddelbart tilgængelig i tilfælde af sjælden anafylaktisk reaktion efter administration af vaccinen.
As with all injectable vaccines, appropriate medical treatment and supervision should always be readily available in case of a rare anaphylactic reaction following the administration of the vaccine.
relevant ændring i det respiratoriske
clinically relevant change in the
Relevante eksempler er cytomegalovirus retinitis, generaliserede og/eller fokale mycobakterielle infektioner og Pneumocystis jiroveci-pneumoni.
Relevant examples are cytomegalovirus retinitis, generalised and/or focal mycobacterial infections, and Pneumocystis jirovecii pneumonia.
Relevante eksempler er cytomegalovirus retinitis, generaliserede og/eller fokale mycobakterielle infektioner og pneumocystis jirovecii pneumoni (tidligere kaldet pneumocystis carinii pneumoni).
Relevant examples are cytomegalovirus retinitis, generalised and/or focal mycobacterium infections, and Pneumocystis jiroveci pneumonia (formerly known as Pneumocystis carinii pneumonia).
Relevante eksempler er cytomegalovirus retinitis, generaliserede og/eller fokale mycobakterielle infektioner og pneumoni fremkaldt af pneumocystis jiroveci (tidligere kendt som pneumocystis).
Relevant examples are cytomegalovirus retinitis, generalised and/or focal mycobacterial infections, and pneumonia caused by Pneumocystis jiroveci (formerly known as Pneumocystis carinii).
Relevante eksempler er cytomegalovirus retinitis, generaliserede og/eller fokale mykobakterielle infektioner og pneumocystis carinii-pneumoni.
Relevant examples are cytomegalovirus retinitis, generalised and/or focal mycobacterium infections, and Pneumocystis carinii pneumonia.
Relevante eksempler er cytomegalovirus retinitis, generaliserede og/eller fokale mykobakterielle infektioner og Pneumocystis jirovecii pneumoni.
Relevant examples are cytomegalovirus retinitis, generalised and/or focal mycobacterial infections, and Pneumocystis jirovecii pneumonia.
Relevante eksempler er cytomegalovirus retinitis, generaliserede og/eller fokale mykobakterielle infektioner og pneumoni forårsaget af Pneumocystis carinii.
Relevant examples are cytomegalovirus retinitis, generalised and/or focal mycobacterial infections, and Pneumocystis carinii pneumonia.
Relevante og følsomme mikroorganismer hos kat er E. coli, Staphylococcus spp., Pasteurella spp., Proteus spp. og Klebsiella spp. (MIC ≤ 0,5 g ibafloxacin/ml).
In cats, relevant susceptible micro-organisms are E.coli, Staphylococcus spp., Pasteurella spp., Proteus spp. and Klebsiella spp. (MIC ≤ 0.5 µg ibafloxacin/ml).
Relevante oplysninger (f.eks. hvor alvorlig bivirkningen er, sværhedsgraden, hyppigheden, tid til opståen, reversibilitet) om følgende sikkerhedsproblemer:
Relevant information (e.g. seriousness, severity, frequency, time to onset, reversibility of the AE as applicable) for the following safety concerns:
Relistor 12 mg Injektion Methylnaltrexonbromid s.c.
Relistor 12 mg Injection Methylnaltrexone bromide SC
Relistor 12 mg injektionsvæske, opløsning, i fyldt injektionssprøjte
Relistor 12 mg solution for injection in pre-filled syringe
Relistor 12 mg injektionsvæske, opløsning, i fyldt injektionssprøjte Methylnaltrexonbromid
Relistor 12 mg solution for injection in pre-filled syringe Methylnaltrexone bromide
Relistor 12 mg/0,6 ml
RELISTOR 12 mg/0.6 mL
Relistor 12 mg/0,6 ml injektionsvæske, opløsning.
Relistor 12 mg/0.6 mL solution for injection
Relistor 8 mg injektion Methylnaltrexonbromid s.c.
Relistor 8 mg injection Methylnaltrexone bromide SC
Relistor 8 mg injektionsvæske, opløsning, i fyldt injektionssprøjte
Relistor 8 mg solution for injection in pre-filled syringe
Relistor 8 mg injektionsvæske, opløsning, i fyldt injektionssprøjte Methylnaltrexonbromid
Relistor 8 mg solution for injection in pre-filled syringe Methylnaltrexone bromide
Relistor anvendes til behandling af forstoppelse forårsaget af opioider (morfinlignende smertestillende lægemidler) og til behandling af moderate til svære smerter, som skyldes langvarig eller femskreden sygdom hos voksne (18 år og derover), når reaktionen på afføringsmidler ikke er tilstrækkelig.
Relistor is used to treat the constipation caused by opioids (painkillers that are related to morphine and used to treat moderate to severe pain due to long-term or advanced diseases) in adults (aged 18 years or over) when the response to laxative medicines has not been sufficient.
Relistor blev givet med 3,2 dages mellemrum (det mediane doseringsinterval i perioden 1 – 39 dage).
Relistor was administered every 3.2 days (median dosing interval, with a range of 1-39 days).
Relistor blev sammenlignet med placebo (en virkningsløs behandling) i to hovedundersøgelser, som omfattede i alt 288 patienter med fremskreden sygdom og forstoppelse forårsaget af opioider.
Relistor has been compared with placebo (a dummy treatment) in two main studies involving a total of 288 patients with an advanced illness and constipation caused by opioids.
Relistor er blevet sammenlignet med placebo hos 496 patienter med forstoppelse forårsaget af opioider, men uden fremskreden sygdom.
Relistor has also been compared with placebo in 496 patients with constipation caused by opioids, but no advanced illness.
Relistor er en injektionsvæske, opløsning, der indeholder det aktive stof methylnaltrexonbromid.
Relistor is a solution for injection that contains the active substance methylnaltrexone bromide.
Relistor er indiceret til behandling af opioidinduceret obstipation hos voksne patienter i alderen 18 år eller ældre, når responset på sædvanlige laksantia har været utilstrækkeligt.
Relistor is indicated for the treatment of opioid-induced constipation when response to laxative therapy has not been sufficient in adult patients, aged 18 years and older.
Relistor er indiceret til behandling af opioidinduceret obstipation hos voksne patienter i alderen 18 år og ældre, når responset på sædvanlige laksantia har været utilstrækkeligt
Relistor is indicated for the treatment of opioid-induced constipation when response to laxative therapy has not been sufficient in adult patients, aged 18 years and older.
Relistor i fyldt injektionssprøjte
Relistor pre-filled syringe
Relistor var mere effektivt end placebo til at stimulere tarmene til at åbne sig.
Relistor was more effective than placebo in stimulating the bowels to open in patients with an advanced illness.
relse
administration
relse
Package
Relvar Ellipta 184 mikrogram/22 mikrogram inhalationspulver fluticasonfuroat/vilanterol
Relvar Ellipta 184 micrograms/22 micrograms inhalation powder fluticasone furoate/vilanterol
Relvar Ellipta 184 mikrogram/22 mikrogram inhalationspulver, afdelt fluticasonfuroat/vilanterol
Relvar Ellipta 184 micrograms/22 micrograms inhalation powder, pre-dispensed fluticasone furoate /vilanterol
Relvar Ellipta 184 mikrogram/22 mikrogram inhalationspulver, afdelt fluticasonfuroat/vilanterol
Relvar Ellipta 184 micrograms/22 micrograms inhalation powder, pre-dispensed fluticasone furoate/vilanterol
Relvar Ellipta 184 mikrogram/22 mikrogram inhalationspulver, afdelt.
Relvar Ellipta 184 micrograms/22 micrograms inhalation powder, pre-dispensed
relvar ellipta 184/22
relvar ellipta 184:22
Relvar Ellipta 184/22 mikrogram er ikke indiceret til KOL-patienter.
Relvar Ellipta 184/22 micrograms is not indicated for patients with COPD.
Relvar Ellipta 92 mikrogram/22 mikrogram inhalationspulver fluticasonfuroat/vilanterol
Relvar Ellipta 92 micrograms/22 micrograms inhalation powder fluticasone furoate/vilanterol
Relvar Ellipta 92 mikrogram/22 mikrogram inhalationspulver, afdelt fluticasonfuroat/vilanterol
Relvar Ellipta 92 micrograms/22 micrograms inhalation powder, pre-dispensed fluticasone furoate /vilanterol
Relvar Ellipta 92 mikrogram/22 mikrogram inhalationspulver, afdelt fluticasonfuroat/vilanterol
Relvar Ellipta 92 micrograms/22 micrograms inhalation powder, pre-dispensed fluticasone furoate/vilanterol
Relvar Ellipta 92 mikrogram/22 mikrogram inhalationspulver, afdelt Relvar Ellipta 184 mikrogram/22 mikrogram inhalationspulver, afdelt
Relvar Ellipta 92 micrograms/22 micrograms inhalation powder, pre-dispensed Relvar Ellipta 184 micrograms/22 micrograms inhalation powder, pre-dispensed
Relvar Ellipta 92 mikrogram/22 mikrogram inhalationspulver, afdelt.
Relvar Ellipta 92 micrograms/22 micrograms inhalation powder, pre-dispensed
relvar ellipta 92/22
relvar ellipta 92:22
Relvar Ellipta 92/22 µg (mikrogram), forbedrede efter 12 ugers behandling det gennemsnitlige FEV1 med 36 ml mere end fluticasonfuroat og med 172 ml mere end placebo; i den høje dosis på 184/22 µg forbedrede det efter 24 ugers behandling FEV1 med 193 ml mere end fluticasonfuroat og med 210 ml mere end sammenligningslægemidlet fluticasonpropionat.
Relvar Ellipta 92/22 microgram improved average FEV1 by 36 ml more than fluticasone furoate and by 172 ml more than placebo after 12 weeks of treatment; when it was used at a higher dose of 184/22 microgram it improved FEV1 by 193 ml more than fluticasone furoate and by 210 ml more than the comparator medicine fluticasone propionate after 24 weeks of treatment.
Relvar Ellipta anvendes desuden til lindring af symptomerne på kronisk obstruktiv lungesygdom (KOL) hos voksne, som tidligere har haft anfald med forværring af sygdommen trods regelmæssig behandling.
Relvar Ellipta is also used to relieve the symptoms of chronic obstructive pulmonary disease (COPD) in adults who have had exacerbations (flare–ups) of the disease in the past despite regular treatment.
Relvar Ellipta bør ikke anvendes i kombination med andre langtidsvirkende beta2-agonister eller lægemidler, der indeholder langtidsvirkende beta2-agonister.
Relvar Ellipta should not be used in conjunction with other long-acting beta2-adrenergic agonists or medicinal products containing long- acting beta2-adrenergic agonists.
Relvar Ellipta bør kun overvejes til gravide, hvis de forventede fordele opvejer risikoen.
Relvar Ellipta should only be considered for pregnant women if the expected benefits outweigh the risks.
Relvar Ellipta er et hvidt pulver.
Relvar Ellipta is a white powder.
Relvar Ellipta er et lægemiddel, der indeholder de to aktive stoffer fluticasonfuroat og vilanterol.
Relvar Ellipta is a medicine that contains the active substances fluticasone furoate and vilanterol.
Relvar Ellipta er indiceret til behandling af astma hos voksne og unge på 12 år og derover, hvor behandling med et kombinationspræparat (langtidsvirkende beta2-agonist og inhalationssteroid) er hensigtsmæssig: hos patienter, der ikke er velkontrolleret på inhalationssteroid og korttidsvirkende beta2-agonist ved behov.
Relvar Ellipta is indicated for the regular treatment of asthma in adults and adolescents aged 12 years and older where use of a combination medicinal product (long-acting beta2-agonist and inhaled corticosteroid) is appropriate: patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short acting beta2-agonists.
Relvar Ellipta indeholder to aktive stoffer.
Relvar Ellipta contains two active substances.
Relvar Ellipta var genstand for tre hovedundersøgelser ved astmabehandling med deltagelse af i alt over 3 200 patienter.
For the treatment of asthma, Relvar Ellipta was investigated in three main studies involving a total of over 3,200 patients.
Relvar Ellipta var i alle styrker mere effektivt til at mindske antallet af anfald med forværring af KOL end vilanterol alene.
Relvar Ellipta at all strengths was more effective in reducing the number of COPD flare-ups than vilanterol alone.
Relvar Ellipta, 184/22 µg, virkede imidlertid ikke bedre end Relvar Ellipta, 92/22 µg.
However, there was no improvement of Relvar Ellipta 184/22 microgram over Relvar Ellipta 92/22 microgram.
Relvar Ellipta, 92/22 µg (mikrogram), (92 µg fluticasonfuroat og 22 µg vilanterol) kan anvendes til behandling af både astma og KOL, mens Relvar Ellipta, 184/22 µg, (184 µg fluticasonfuroat og 22 µg vilanterol) kun kan anvendes til behandling af astma.
Relvar Ellipta 92/22 microgram (92 micrograms of fluticasone furoate and 22 micrograms of vilanterol) can be used for the treatment of both asthma and COPD, while Relvar Ellipta 184/22 microgram (184 micrograms of fluticasone furoate and 22 micrograms of vilanterol) can only be used for the treatment of asthma.
Remicade 100 mg pulver til koncentrat til infusionsvæske, opløsning infliximab
Remicade 100 mg powder for concentrate for solution for infusion Infliximab
Remicade anvendes også til patienter i alderen mellem seks og 17 år med svær, aktiv Crohns sygdom eller svær aktiv colitis ulcerosa, når de ikke har reageret på eller ikke kan tåle andre lægemidler eller behandlinger.
Remicade is also used in patients aged between six and 17 years with severe, active Crohn’s disease or severely active ulcerative colitis, when they have not responded to or cannot take other medicines or treatments.
Remicade anvendes sammen med methotrexat (et lægemiddel, der virker på immunsystemet),
Remicade is used with methotrexate (a medicine that acts on the immune system);
Remicade blev givet sammen med methotrexat og sammenlignet med methotrexat alene.
Remicade was given with methotrexate and compared with methotrexate alone.
Remicade bør seponeres hos patienter, hvor HBV reaktiveres, og effektiv antiviral behandling med passende understøttende behandling bør igangsættes.
In patients who develop HBV reactivation, Remicade should be stopped and effective antiviral therapy with appropriate supportive treatment should be initiated.
Remicade er et antiinflammatorisk lægemiddel.
Remicade is an anti-inflammatory medicine.
Remicade er et pulver, der blandes til en opløsning til infusion (drop i en vene).
Remicade is a powder that is made up into a solution for infusion (drip into a vein).
Remicade er indiceret til behandling af svær, aktiv Crohns sygdom hos børn og unge mellem 6 og 17 år, som ikke har responderet på konventionel behandling inklusive kortikosteroid, immunmodulator og primær ernæringsbehandling, eller som er intolerante over for eller hvor der er kontraindikationer mod sådanne behandlinger.
Remicade is indicated for treatment of severe, active Crohn’s disease, in children and adolescents aged 6 to 17 years, who have not responded to conventional therapy including a corticosteroid, an immunomodulator and primary nutrition therapy; or who are intolerant to or have contraindications for such therapies.
Remicade gives normalt som 3 mg pr. kg kropsvægt til rheumatoid arthritis, selv om dosis om nødvendigt kan sættes op.
Remicade is usually given as 3 mg per kilogram body weight in rheumatoid arthritis, although the dose can be increased if necessary.
Remicade gives som en infusion, der varer en eller to timer.
Remicade is given as an infusion lasting one or two hours.
Remicade indeholder det aktive stof infliximab.
Remicade contains the active substance called infliximab.
Remicade leveres som et hætteglas (glasflaske) indeholdende et pulver til koncentrat til infusionsvæske, opløsning.
Remicade is supplied as a glass vial containing a powder for concentrate for solution for infusion.
Remicade må ikke anvendes til patienter, som tidligere har været overfølsomme (allergiske) over for infliximab, eller som er overfølsomme over for museproteiner eller et andet af de øvrige indholdsstoffer i Remicade.
Remicade must not be used in patients who have experienced hypersensitivity (allergy) to infliximab in the past, or who are hypersensitive (allergic) to mouse proteins or any of the other ingredients of Remicade.
Remicade må kun anvendes til børn, hvis de behandles for Crohns sygdom eller colitis ulcerosa.
Remicade should only be used in children if they are being treated for Crohn’s disease or ulcerative colitis.
Remicade påvirker i mindre grad evnen til at føre motorkøretøj eller betjene maskiner.
Remicade may have a minor influence on the ability to drive and use machines.
Remicade skal gives under overvågning og monitorering af en speciallæge, som har erfaring i diagnosticering og behandling af de sygdomme, som kan behandles med Remicade.
Remicade must be given under the supervision and monitoring of a specialised doctor who has experience in the diagnosis and treatment of the diseases that Remicade can be used to treat.
Remicade tilhører en medicingruppe kaldet ”TNF-blokkere”.
Remicade belongs to a group of medicines called ‘TNF blockers’.
Remicade virker ved at blokere virkningen af et protein, der hedder ”tumornekrosefaktor alfa” (TNF).
Remicade works by blocking the action of a protein called ‘tumour necrosis factor alpha’ (TNF).